drugset / Trial / NCT01514110

Gastric Cancer RAD001 Study

NCT01514110

Phase 1/2 Completed 35 enrolled Chinese University of Hong Kong
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine dose limiting toxicities (DLT) and maximum tolerated dose (MTD) of RAD001, as well as to assess tumor response and overall survival.

Timeline

Start
2008-01-23
Primary completion
2019-03-06
Completion
2019-03-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Everolimus Small molecule

Indications